AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.11 +1.71%

+$0.04 today

Market cap
$214.74M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.12M

Average 0.32M

ACIU Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

AC Immune S.A.NASDAQ: ACIU

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q1 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 100.0%, up 0.0 pp year over year. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
100.0%+229.1 pp YoY
LTMMar 2026
100.0%+0.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year+229.1 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+229.1pp

Gross Margin vs competitors

How ACIU compares with its peers on the latest reported figures

  • ACIU's LTM Mar 2026 gross margin of 100.0% is the highest of the 6 companies compared; the peer median is 52.5%.
  • Its year-over-year change of +0.0 pp is the 3rd highest of 4, against a peer median of +0.5 pp.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of +7.3 pp.
ACIU Competitors Peer median
Gross Margin for ACIU and competitors
Company Period LTM level YoY 3-year change
ACIUAC Immune S.A.LTM Mar 2026100.0% +0.0 pp+0.0 pp
CLLSCellectis S.A.LTM Mar 202681.9% +0.5 pp+30.8 pp
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
AMRNAmarin Corporation plcLTM Mar 202652.5% +18.0 pp-9.1 pp
MREOMereo BioPharma Group plcLTM Mar 2026-105.7% ——
LYELLyell Immunopharma, Inc.LTM Mar 2026-7422.6% -7522.6 pp-32052.8 pp
DRTSAlpha Tau Medical Ltd.FY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
ANNXAnnexon, Inc.FY2025— ——
CTNMContineum Therapeutics, Inc. Class A Common StockFY2025— ——
ALDXAldeyra Therapeutics, Inc.FY2025— ——
Peer median (excluding ACIU) 52.5%+0.5 pp+7.3 pp

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.